Krystal Biotech, Inc. (KRYS)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-14 · Source: TEK2day Finance
Key Metrics
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 97.8M | 107.1M | 116.4M | 119.2M |
| Gross Profit | 93.5M | 100.5M | 110.0M | 112.8M |
| Operating Income | 41.4M | 44.3M | 53.7M | 58.4M |
| Net Income | 79.4M | 51.4M | 55.9M | 54.8M |
| Diluted EPS | $2.66 | $1.70 | $1.83 | $1.79 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 50.7M | 290.5M | 389.1M |
| Gross Profit | 0.00 | 47.6M | 270.5M | 366.1M |
| Operating Income | (120.2M) | (97.1M) | 103.2M | 161.3M |
| Net Income | (140.0M) | 10.9M | 89.2M | 204.8M |
| Diluted EPS | $-5.49 | $0.39 | $3.00 | $6.84 |